## Summary of Product Characteristics

```
1 \text { NAME OF THE MEDICINAL PRODUCT}
Zofran 4 mg film-coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains ondansetron 4 mg as ondansetron hydrochloride dihydrate.
Excipient(s) with known effect: Lactose
For the full list of excipients, see section 6.1
```


## 3 PHARMACEUTICAL FORM

```
Product imported from Greece or Poland
Film-coated tablets
Yellow, oval, film coated tablet engraved "GLAXO" on one face and "4" on the other or
Yellow, oval, film-coated tablet engraved 'GX ET 3' on one face and blank on the other.
```


## 4 CLINICAL PARTICULARS

As per PA0711/327/003

## 5 PHARMACOLOGICAL PROPERTIES

As per PA0711/327/003

6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

## Core:

Lactose
Microcrystalline cellulose
Maize starch
Magnesium stearate

Film-coating:
Hypromellose
Titanium dioxide (E171)
Iron oxide (E172)

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the container and outer package of the product on the market in the country of origin.

### 6.4 Special precautions for storage

Do not store above $30^{\circ} \mathrm{C}$.

### 6.5 Nature and contents of container

Blister packs containing 10, 15 or 30 tablets in an outer cardboard carton.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

Swallow whole with a glass of water.

## 7 PARALLEL PRODUCT AUTHORISATION HOLDER

PCO Manufacturing Ltd.
Unit 10, Ashbourne Business Park
Rath
Ashbourne
Co. Meath
Ireland

## 8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA0465/113/001

## 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 17 October 2003

Date of last renewal: 17 October 2008

10 DATE OF REVISION OF THE TEXT

April 2023

